Finepoint Capital LP Has $27.05 Million Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Finepoint Capital LP raised its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 748,752 shares of the company's stock after buying an additional 97,900 shares during the quarter. SpringWorks Therapeutics comprises 1.7% of Finepoint Capital LP's investment portfolio, making the stock its 6th largest position. Finepoint Capital LP owned approximately 1.01% of SpringWorks Therapeutics worth $27,052,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Huntington National Bank lifted its holdings in SpringWorks Therapeutics by 38.2% in the fourth quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after buying an additional 192 shares during the period. AlphaQuest LLC lifted its stake in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter valued at approximately $45,000. KBC Group NV boosted its position in shares of SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after purchasing an additional 978 shares in the last quarter. Finally, US Bancorp DE raised its holdings in SpringWorks Therapeutics by 56.0% in the fourth quarter. US Bancorp DE now owns 4,336 shares of the company's stock worth $157,000 after purchasing an additional 1,556 shares in the last quarter.

Remove Ads

SpringWorks Therapeutics Stock Performance

Shares of SWTX traded up $0.83 on Friday, hitting $35.26. 649,519 shares of the stock traded hands, compared to its average volume of 1,367,197. The company has a market capitalization of $2.64 billion, a PE ratio of -10.12 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a one year low of $28.21 and a one year high of $62.00. The business has a 50 day simple moving average of $48.67 and a 200 day simple moving average of $40.01.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The business had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. On average, equities analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Insider Buying and Selling at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $54.36, for a total value of $1,617,210.00. Following the transaction, the insider now owns 50,762 shares of the company's stock, valued at approximately $2,759,422.32. This represents a 36.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bhavesh Ashar sold 1,016 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the completion of the transaction, the insider now directly owns 62,053 shares in the company, valued at $3,797,023.07. The trade was a 1.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 440,766 shares of company stock worth $24,402,956. Insiders own 7.61% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SWTX shares. HC Wainwright restated a "buy" rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday, February 21st. Wedbush restated an "outperform" rating and issued a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Guggenheim lowered their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Finally, Evercore ISI upped their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics currently has an average rating of "Buy" and an average price target of $73.20.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.